title: CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients.
abstract: The clinical course of 50 patients with low-grade glioma (31 male, 19 female) undergoing surgery at a single Institution from 1992 to 1996 was analyzed in relationship with known prognostic factors as far as time to tumor progression (TTP) and survival time (ST) are concerned. Moreover, microvessel density (MVD) and expression of the angiogenesis-related chemokine CXCL12 were investigated in surgical specimens. Age at diagnosis ranged from 1 to 68 years (median 30). Histology revealed 11 fibrillary, 6 protoplasmatic, 5 gemistocytic astrocytoma, 18 oligoastrocytoma and 10 oligodendroglioma. Mean follow-up was 86 months. Four patients were lost to follow-up. Of the remaining 46, twenty-four have shown disease progression and 14 have died. Median overall survival was not achieved; an estimated 75% percentage of survivors was found at 78 months. Complete gross tumor removal was associated to a longer TTP (P = 0.04 logrank). Of the investigated immunohistochemical parameters, while MVD was not predictive of subsequent TTP, expression of CXCL12 was associated with a significantly shorter TTP (P = 0.01 logrank): this predictive value remained significant (P = 0.02) at multivariate analysis. The data suggest the possible prognostic value for CXCL-12 (an angiogenesis- and tumor-growth-related chemokine) on TTP in low-grade gliomas.
authors.affiliation: Istituto Nazionale Neurologico C.Besta, Via Celoria 11, 20133 Milano, Italy. salmaggi@istituto-besta.it
authors.forename: A
authors.initials: A
authors.lastname: Salmaggi
authors.forename: M
authors.initials: M
authors.lastname: Gelati
authors.forename: B
authors.initials: B
authors.lastname: Pollo
authors.forename: C
authors.initials: C
authors.lastname: Marras
authors.forename: A
authors.initials: A
authors.lastname: Silvani
authors.forename: M R
authors.initials: MR
authors.lastname: Balestrini
authors.forename: M
authors.initials: M
authors.lastname: Eoli
authors.forename: L
authors.initials: L
authors.lastname: Fariselli
authors.forename: G
authors.initials: G
authors.lastname: Broggi
authors.forename: A
authors.initials: A
authors.lastname: Boiardi
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D001932:Brain Neoplasms / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology; D054377:Chemokine CXCL12; D019743:Chemokines, CXC / Q000096:biosynthesis*; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005910:Glioma / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D019743:Chemokines, CXC